Half-Year Report, H1 2026

20 August 2026

ViroGates

Forward-looking statements

Certain information set forth and given in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates' business, projects and joint ventures; (iii) execution of ViroGates' vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates' projects; (v) completion of ViroGates' projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates' current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Contents

On 20 August 2026, the Board of Directors approved the interim report for the first half of 2026 (the period 1 January – 30 June 2026) for ViroGates A/S.

The interim report is unaudited.

Contents

Letter from the CEO

We are happy to report that revenue for the first half of 2026 rose markedly compared with the same period last year. However, the increase largely reflects our U.S. partner taking delivery of the minimum order under our distribution agreement, and not yet a broad-based rollout in the U.S. market. We remain closely engaged with suPARbio™ to support where we can and enter the second half of the year with enthusiasm for our strategy, partnerships, and revamped commercial organization.

The first half of 2026 saw a notable year-on-year increase in revenue, which is greatly encouraging. At the same time, we want to be transparent about its underlying dynamics. A large part of the increase is attributable to deliveries to our U.S. commercial partner, suPARbio™, in accordance with the minimum binding order set forth in our 2024 distribution agreement.

We remain very enthusiastic about this collaboration and the opportunity it represents for suPARnostic® in the U.S. longevity and preventive health market. We remain in close, ongoing contact with suPARbio™ and continue to support them operationally – from technical and product guidance to the practical work involved in getting suPARnostic® set up and running in laboratories – as they build out testing capacity. What remains pending is the introduction of suPARnostic® into higher-volume commercial sales channels to enable testing at scale. We look forward to reporting on that progress as it materializes.

Together with our continued partner Swedish Orphan Biovitrum (Sobi), we submitted our De Novo application to the U.S. FDA for suPARnostic® TurbiLatex. This was an important milestone on the path to U.S. regulatory clearance and a prerequisite for broader commercialization of this product line in the U.S. market. We expect the FDA to request additional data as part of its review, and generating and submitting that data will represent a significant ongoing commitment for ViroGates.

Our suPARnostic® POC+ device, developed in collaboration with GENSPEED Biotech and designed for decentralized, near-patient longevity testing, has moved from proof of concept to further testing and validation. This is an encouraging step; further testing is required before we can confirm performance under standard operating conditions and move toward market registration under the IVDR (market authorization in the EU). We will update the market as this work progresses.

After the reporting period, on 3 August 2026, we announced changes to our commercial organization, moving from a traditional, sales-led model toward a business-development model built around larger, more scalable partnerships with clinics, laboratories, and commercial partners. Alexandre ("Alex") Delatour has joined as our newly appointed VP of Business Development, reporting to the CEO, while Thomas Krarup, VP of Sales & Marketing, has decided to leave ViroGates at the end of September. We remain very optimistic about this transition but also recognize that organizational change does not translate immediately into a comparable step-up in commercial output. Our expectations for the second half of 2026 are adjusted to account for this.

ViroGates will also focus on the transition to the IVDR regulatory scheme in the EU and dedicate resources to the next steps in upgrading ISO systems and technical documentation to prepare for an audit by the Notified Body.

As a result of the above developments, we recently adjusted our financial guidance, stating expected revenue of DKK 6.5-8 million, with EBIT maintained at DKK -10 to -12 million (cf. Company Announcement No. 7-2026).

We enter the second half of 2026 with a U.S. partnership operationally geared for growth, regulatory progress with the FDA, an evolving product pipeline, and a commercial organization reshaped for scale. Our focus now is to turn these building blocks into evidence-based outcomes for healthcare providers and individuals, as well as to shareholder value.

Jakob Knudsen
CEO

The performance of H1 2026 reflects a marked increase in revenue, driven by our U.S. partner taking delivery of their minimum order – actual roll-out to end users in the U.S. remains the key milestone ahead

Financial results in H1, 2026

(H1, 2025 results in brackets)

- Revenue increased by 173% to TDKK 5,101 (TDKK 1,869)
- Operating expenses amounted to TDKK -8,253 (TDKK -9,485)
- Operating loss decreased by 33% to TDKK -3,944 (TDKK -5,871)
- Net loss decreased by 47% to TDKK -3,199 (TDKK -6,031)
- Cash and cash equivalents at the end of the period amounted to 17,635 (TDKK 11,878)



"The first half of 2026 showed a significant increase in revenue compared with the same period last year, which is very encouraging. As a result, we recently communicated revised guidance for the year. It is, however, important to be clear about what sits behind the development: the increase largely reflects suPARbio™, our U.S. partner, taking delivery of the minimum order under our 2024 distribution agreement – in effect, building up stock rather than yet reflecting testing at scale. This also drove both operating loss and net loss down year-over-year. We remain closely engaged with suPARbio™ and continue to support them operationally as they build out capacity."

Josephine Baum Jørgensen, CFO

In H1 2026, ViroGates advanced its collaboration with Sobi and made an FDA submission, developed suPARnostic® POC+ further, and took important steps in the U.S. commercial partnership

Business highlights in H1 2026

- ViroGates and Sobi finalized the clinical and analytical development work underpinning suPARnostic® TurbiLatex for commercial use in the U.S. in combination with the pharmaceutical product Kineret® (anakinra), and compiled the full application for a De Novo filing with the U.S. FDA – submitted in April 2026, as announced in Company Announcement No. 3-2026 of 8 April 2026.
- ViroGates and GENSPEED Biotech advanced suPARnostic® POC+ from proof of concept into further testing and validation during the period. This is needed before an IVDR application in the EU can be compiled.
- ViroGates' U.S. partner, suPARbio™, took delivery of the minimum order under the 2024 distribution agreement, building up stock ahead of scalable commercial launch. A tangible step in the U.S. roll-out, which ViroGates continues to support closely.
- By the end of H1 2026, ViroGates reports a recurring customer base of 20 customers (19 at the end of H1 2025).

sobi

FDA U.S. FOOD & DRUG ADMINISTRATION

The full-year financial guidance for 2026 is maintained at 6.5 to 8 DKKm in revenue and -10 to -12 DKKm in EBIT

Full-year outlook, 2026

- The strategic refocusing that ViroGates is undergoing continues to progress; however, such a transition inherently involves a degree of uncertainty. An evaluation of sales data from H1 2026 shows that longevity-related customers now account for a substantial share of revenue. This marks a meaningful step up from prior periods, but currently also reflects a single large distribution account rather than broad-based, recurring demand across the segment. ViroGates continues working to build a more scalable longevity customer base by targeting laboratories, clinic chains, and new partners specializing in preventive health services.
- In parallel, ViroGates continues to work closely with suPARbio™, serving the U.S. longevity market. The recently revised guidance reflects the significant potential of the partnership, while accounting for the fact that the actual roll-out and testing volumes in the U.S. market are yet to materialize. The U.S. longevity, prevention, and population-wide health screening continues to be a key market for suPARnostic®.
- ViroGates continues its collaboration with Sobi to obtain marketing clearance for suPARnostic® TurbiLatex in the US. The De Novo application, submitted in April 2026 (cf. Company Announcement No. 3-2026), remains under review. This work is not expected to have a revenue impact within the remainder of the year.
- Following the changes to ViroGates' commercial organization announced on 3 August 2026 (cf. Company Announcement No. 6-2026), guidance accounts for the implementation of the new structure and personnel during H2 2026.
- The recently revised financial guidance for 2026, as communicated in Company Announcement No. 7-2026, is maintained. ViroGates closely monitors financial performance and will update its guidance accordingly.

Full-year guidance, 2026

6.5 to 8 DKKm

revenue in 2026

-10 to -12 DKKm

EBIT in 2026

Contents

In H1 2026, ViroGates deepened its commercial alliances and laid the groundwork for a go-to-market model built on scale

Jakob Knudsen

A shift toward scalable, partnership-led growth

As demand for preventive health and longevity grows, ViroGates is evolving its go-to-market strategy. We are focusing on a commercial model to pursue more scalable partnerships with established players who have direct market access.

suPARbio™, our U.S. commercial partner, is a great example of this approach: a partnership designed to reach the U.S. longevity and health-management market, rather than one clinic relationship at a time.

The dynamic above is also one of the main reasons we have restructured internally. The role of the newly created Vice President of Business Development position is to help build such partnerships and market access with healthcare providers and commercial players across key markets, and to refine and accelerate this new go-to-market strategy (cf. Company Announcement No. 6-2026 of 3 August 2026). We see this as the natural next step in the same direction we have been moving throughout H1 2026: fewer, larger relationships that can scale faster than a traditional sales model.

Optimizing POC+ for longevity

The revised suPARnostic® POC+ has been optimized specifically for the preventive health and longevity market, with improved precision in the lower suPAR range relevant to this population. The remaining milestone is to complete analytical and minor clinical validation.

The POC+ format is a natural fit for our scalability ambition: unlike testing that requires an IV blood draw, a fingerprick product can be offered far beyond the current clinical setting, e.g., at pharmacies, wellness and longevity clinics, meaningfully widening the population that can access suPAR testing as part of everyday health monitoring.

Collaboration with Sobi

We have continued our close collaboration with Sobi on the regulatory process for U.S. market clearance of suPARnostic® TurbiLatex. As previously communicated, the pathway for U.S. entry is through a De Novo application, as the product is considered a novel, low-to-moderate risk medical device without a suitable predicate for a 510(k) clearance.

The application includes analytical validation data, clinical data from the SAVE-MORE phase 3 trial, and additional supporting clinical evidence obtained specifically for this project and was submitted to the FDA in April 2026 (cf. Company Announcement No. 3-2026).

Financial highlights

Key figures and ratios

	DKK ('000) unless otherwise stated	H1, 2026	H1, 2025	% change	2025
INCOME STATEMENT	Net revenue	5,101	1,869	173%	5,307
	Other income	224	2,999	-93%	3,597
	Gross profit/loss	4,309	3,615	19%	6,621
	Operating profit/loss	-3,944	-5,871	-33%	-10,472
	Financial income and expenses, net	199	-514	-139%	-757
	Profit/loss for the period before tax	-3,745	-6,385	-41%	-11,229
	Profit/loss for the period	-3,199	-6,031	-47%	-10,397
BALANCE SHEET	Assets	22,077	17,985	23%	30,589
	Equity	16,204	4,765	240%	19,403
	Liabilities	5,873	8,976	-35%	3,475
CASH FLOW STATEMENT	Cash flows from operating activities	-8,090	-76	N/A	-4,125
	Cash flows from investment activities	0	0	-	5
	Cash flows from financing activities	-572	-255	125%	18,209
	Investment in tangible fixed assets	0	0	-	0
	Total cash flows	-8,662	-331	N/A	14,089

DKK unless otherwise stated	H1, 2026	H1, 2025	% change	2025
Rate of return (%)	-110,43	-121,75	-9%	-290,60
Share price, end of period	10.90	7.80	40%	13.45
Equity ratio (%)	73%	26%	177%	63%
Employees, end of period (#)	7	7	-	7

Note: N/A = not meaningful. Percentage changes are not presented where the comparison-period base value is too small to provide a meaningful denominator, as the resulting percentage would not reflect meaningful information about underlying performance.

Financial highlights (continued)

Revenue by product

DKKm, % of total

- TurbiLatex
- Quick Triage
- ELISA
- Other



Revenue by geographic area

DKKm, % of total

- Europe
- North America
- ROW



Note: Regional split uses the United Nations geoscheme created by the UNSD.

Financial highlights (continued)

Recurring customers by segment

(# by end of period)





"In the first half of 2026, our routine business kept moving toward longevity and preventive care, as chronic inflammation gains ground as a key marker of long-term health risk. We are focused on deepening ties with central labs, clinic networks, and specialized partners who are embedding suPAR into routine workflows rather than using it as a one-off. As I prepare to step down from my role at the end of September, I'll be following ViroGates' continued progress closely – it's an exciting road ahead, and I'm confident the team will keep building on this momentum."

Thomas Krarup, VP of Global Sales & Marketing

Note: A recurring customer is defined as a customer that has placed at least two orders within the trailing 12 months, with a combined order value exceeding EUR 10,000. Clinical routine customers are those using suPARnostic® products in routine patient or client handling and processes (e.g. clinics, laboratories, or hospitals), while research customers are those using suPARnostic® products for research purposes (e.g. CROs, university hospitals, or organizations using suPARnostic® in trials and studies).

Contents

Income Statement

PROFIT & LOSS *Amounts in DKK ('000)*	Note	Q2, 2026	Q2, 2025	% change	H1, 2026	H1, 2025	% change	2025
Net revenue		**3,798**	**667**	**469%**	**5,101**	**1,869**	**173%**	**5,307**
Other income		224	2,999	-93%	224	2,999	-93%	3,597
Cost of goods/services sold		-688	-584	18%	-1,015	-1,254	-19%	-2,283
Gross profit		**3,334**	**3,082**	**8%**	**4,309**	**3,615**	**19%**	**6,621**
Sales and distribution costs	1	-1,473	-1,539	-4%	-2,874	-2,958	-3%	-5,365
Research and development costs		-2,025	-3,703	-45%	-3,784	-4,755	-20%	-8,143
Administrative costs		-908	-959	-5%	-1,595	-1,772	-10%	-3,585
Operating loss		**-1,073**	**-3,118**	**-66%**	**-3,944**	**-5,871**	**-33%**	**-10,472**
Financial income		411	32	N/A	419	41	N/A	47
Financial expenses		-109	-294	-63%	-221	-555	-60%	-803
Loss before tax		**-770**	**-3,380**	**-77%**	**-3,745**	**-6,385**	**-41%**	**-11,229**
Tax on profit/loss for the period	2	183	133	37%	546	354	54%	832
Loss for the period		**-588**	**-3,247**	**-82%**	**-3,199**	**-6,031**	**-47%**	**-10,397**
Proposed distribution of loss								
Retained profit		-588	-3,247	-82%	-3,199	-6,031	-47%	-10,397
Total		**-588**	**-3,247**	**-82%**	**-3,199**	**-6,031**	**-47%**	**-10,397**

Balance Sheet

ASSETS *Amounts in DKK ('000)*	Note	Q2, 2026	Q2, 2025	% change	2025
Rent deposit and other receivables		186	181	3%	186
Fixed asset investments	**3**	**186**	**181**	**3%**	**186**
Finished goods and goods for resale		1,451	2,373	-39%	1,754
Inventories		**1,451**	**2,373**	**-39%**	**1,754**
Trade receivables		409	1,646	-75%	1,166
Other receivables		346	259	33%	227
Corporation tax receivable		1,378	1,189	16%	832
Prepayments and accrued income		673	459	46%	128
Receivables		**2,805**	**3,553**	**-21%**	**2,353**
Cash and cash equivalents		**17,635**	**11,878**	**48%**	**26,297**
Current assets		**21,891**	**17,804**	**23%**	**30,403**
Assets		**22,077**	**17,985**	**23%**	**30,589**

EQUITY AND LIABILITIES *Amounts in DKK ('000)*	Note	Q2, 2026	Q2, 2025	% change	2025
Share capital		9,284	7,737	20%	9,284
Retained profit		6,920	-2,972	-333%	10,119
Equity	**4**	**16,204**	**4,765**	**240%**	**19,403**
EIFO loan		2,700	3,931	-31%	3,330
Non-current liabilities		**2,700**	**3,931**	**-31%**	**3,330**
EIFO loan		1,233	1,114	11%	1,293
Trade payables		948	1,704	-44%	632
Other liabilities		992	6,471	-85%	5,931
Current liabilities		**3,173**	**9,289**	**-66%**	**7,856**
Liabilities		**5,873**	**13,220**	**-56%**	**11,186**
Equity and liabilities		**22,077**	**17,985**	**23%**	**30,589**
Contingencies	**5**				

Cash Flow Statement

CASH FLOW *Amounts in DKK ('000)*	**Note**	**Q2, 2026**	**Q2, 2025**	**% change**	**H1, 2026**	**H1, 2025**	**% change**	**2025**
Profit/loss for the period		-588	-3,247	-82%	-3,199	-6,031	-47%	-10,397
Reversed tax on profit/loss for the period		183	-133	-237%	546	-354	-254%	3
Corporation tax received		0	0	-	0	0	-	835
Change in inventory		127	-200	-163%	303	438	-31%	1,057
Change in receivables		-78	1,784	-104%	-453	182	-348%	544
Change in current liabilities (ex bank and tax)		-3,998	2,702	-248%	-5,287	5,688	-193%	3,833
Cash flows from operating activity		**-4,354**	**907**	**-580%**	**-8,090**	**-76**	**N/A**	**-4,125**
Purchase of tangible fixed assets		0	0	-	0	0	-	0
Purchase of financial assets		0	0	-	0	0	-	5
Cash flows from investing activity		**0**	**0**	**-**	**0**	**0**	**-**	**5**
Subscription of share capital		0	0	-	0	0	-	19,005
Loan		-291	-255	14%	-572	-255	125%	-795
Cash flows from financing activity		**-291**	**-255**	**14%**	**-572**	**-255**	**125%**	**18,209**
Change in cash and cash equivalents		-4,645	652	N/A	-8,662	-330	N/A	14,089
Cash and cash equivalents at 1 April/1 January		22,280	11,226	98%	26,297	12,208	115%	12,208
Cash and cash equivalents at end of period		**17,635**	**11,878**	**48%**	**17,635**	**11,878**	**48%**	**26,297**
Specification of cash and cash equivalents at end of period:								
Cash and cash equivalents		17,635	11,878	48%	17,635	11,878	48%	26,297
Cash and cash equivalents		**17,635**	**11,878**	**48%**	**17,635**	**11,878**	**48%**	**26,297**

Notes to the financial statements

1 Staff costs

Amounts in DKK ('000) unless otherwise stated	Q2, 2026	Q2, 2025	% change	2025
Average number of employees (#)	7	7	0%	7
Sales & Marketing	1,066	1,043	2%	3,761
Research & Development	704	681	3%	2,456
Administration	363	404	-10%	1,458
Total staff costs	**2,132**	**2,128**	**0%**	**7,676**

The remuneration for the Board of Directors and Executive Management are published annually in the Company's Remuneration Report in connection with the Annual Report.

2 Tax on profit/loss for the period

Amounts in DKK ('000)	Q2, 2026	Q2, 2025	% change	2025
Calculated tax on taxable income	183	133	37%	832
Total	**183**	**133**	**37%**	**832**

3 Fixed asset investments

Amounts in DKK ('000)	Q2, 2026	Q2, 2025	% change	2025
Rent deposit and other receivables				
Cost at 1 April 2026 / 2025	186	181	3%	181
Additions	**0**	**0**	**-**	**5**
Cost at Q2 2026, Q2 2025, 2025	**186**	**181**	**3%**	**186**
Carrying amount of Q2 2026, Q2 2025, 2025	**186**	**181**	**3%**	**186**

Notes to the financial statements (continued)

4 Equity

Amounts in DKK	Q2, 2026	Q2, 2025	% change	2025
Share capital	9,284,476	7,737,064	20%	7,737,064
Retained profit	10,118,599	3,058,415	231%	3,058,415
Equity at 1 April	**19,403,075**	**10,795,479**	**80%**	**10,795,479**
Capital increase (share capital)	0	0	-	1,547,412
Capital increase (retained profit)	0	0	-	17,717,867
Cost regarding capital increase	0	0	-	-260,741
Proposed distribution of loss to retained profit	-3,199,095	-6,030,848	-47%	-10,396,943
Equity end of period	**16,203,979**	**4,764,631**	**240%**	**19,403,075**

The Company's share capital consists of 9,284,476 shares of nom. 1 kr.

The Company has 2.585 treasury shares of nom. 1 kr. which equals 0.03% of the total share capital.

Under a resolution passed by the General Meeting, the Company may acquire treasury shares up to 10% of the share capital.

5 Contingencies

The Company has provided a guarantee in the form of a bank deposit of DKK ('000) 50 as security for all balances with Danske Bank.

6 Other external expenses

Amounts in % of total expenses	Q2, 2026	Q2, 2025	% change	2025
Sales expenses (incl. staff) in % of total expenses	33.4%	24.8%	35%	31.4%
R&D expenses (incl. staff) in % of total expenses	46.0%	59.7%	-23%	47.6%

Active management & board warrant programs (as of 31 March 2026)

2019 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Jakob Knudsen (CEO)	56,439 (100%)	13,253 (23%)	16,931 (30%)	26,255 (47%)	26,255 (47%)
Thomas Krarup (VP S&M)	20,209 (100%)	10,102 (50%)	1,012 (5%)	9,095 (45%)	9,095 (45%)
Jesper Eugen-Olsen (CSO)	8,084 (100%)	5,051 (62%)	0 (0%)	3,033 (38%)	3,033 (38%)

2019 program details

- Strike price at 35 DKK
- 12% annual price increase from vesting date
- Expiry five years from vesting date

2022 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Other employees	12,500 (100%)	0 (0%)	0 (0%)	12,500 (100%)	12,500 (100%)
Patrik Dahlen (Chairman)	31,700 (100%)	0 (0%)	0 (0%)	29,322 (92%)	31,700 (100%)
Válerie Soulier (BM)	9,510 (100%)	0 (0%)	0 (0%)	8,797 (93%)	9,510 (100%)
Josephine Baum (CFO)	30,000 (100%)	0 (0%)	0 (0%)	23,250(78%)	30,000 (100%)

2022 program details

- Strike price at 129 DKK (other employees), 57.8 DKK (BoD), and 49.50 DKK (CFO)
- 12% annual price increase from vesting date
- Expiry five years from vesting date

2025 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Jakob Knudsen (CEO)	55,000 (100%)	0 (0%)	0 (0%)	17,187 (31%)	55,000 (100%)
Jesper Eugen-Olsen (CSO)	30,000 (100%)	0 (0%)	0 (0%)	9,375 (31%)	30,000 (100%)
Thomas Krarup (VP S&M)	25,000 (100%)	0 (0%)	0 (0%)	7,812 (31%)	25,000 (100%)
Josephine Baum (CFO)	15,000 (100%)	0 (0%)	0 (0%)	4,687 (31%)	15,000 (100%)
Other employees	5,000 (100%)	0 (0%)	0 (0%)	1,563 (31%)	5,000 (100%)

2025 program details

- Strike price at 13 DKK
- 12% annual price increase from vesting date
- Expiry five years from vesting date

Note: Numbers may not add up due to rounding. Mark Da Silva (resigned CFO) still has 11,242 outstanding warrants in the 2019 warrant program. A group of employees no longer employed by ViroGates still has 3,625 outstanding warrants in total in the 2022 program. The 2015 warrant program is not listed above, as all non-exercised warrants in the program have expired.

Shareholdings of the board and management

Management (role)	Executive Management[1]	Management	PDMR[2]	Shares (#, end of Q2, 2026)	Shares (#, end of Q1, 2026)	Shares (#, end of last year)
Jakob Knudsen (CEO)	Yes	Yes	Yes	118,914	118,914	118,914
Josephine Baum Jørgensen (CFO)	No	Yes	Yes	1,200	1,200	1,200
Thomas Krarup (VP Sales & Marketing)	No	Yes	Yes	16,116	16,116	16,116
Jesper Eugen-Olsen (CSO)	No	Yes	No	304,205	301,558	301,558

Board (role)	PDMR[2]	Shares (#, end of Q1, 2026)	Shares (#, end of Q4, 2025)	Shares (#, end of last year)
Patrik Dahlén (Chairman)	Yes	10,570	10,570	10,570
Lars Kongsbak (Board member)	Yes	6,968	6,968	6,968
Valérie Soulier (Board member)	Yes	0	0	0

Note: 1) Executive management registered with the Danish Business Authority; 2) Person Discharging Managerial Responsibilities (permanent insider with access to all information).

ViroGates

Trading windows for persons discharging managerial responsibilities



Trading windows for PDMRs

- **Closed periods:** In accordance with MAR, ViroGates has a closed period of 30 days before the announcement of an interim financial report or a year-end report
- **Open periods:** ViroGates has an open period of six weeks after the announcement of an interim financial report or a year-end report (if an open period of a previous report overlaps a closed period of an upcoming report, the closed period applies)

Note: PDMRs can only trade shares during open trading windows given no insider information at the time of trading.

Contents

Statement by the Board of Directors and Executive Management

Statement

Today, the Board of Directors and the Executive Management have discussed and approved the Annual Report of ViroGates A/S for the first half year of 2026 (1 January – 30 June 2026).

The interim report has been created in accordance with IAS 34, Interim Financial Reporting as approved by the EU and additional disclosure requirements for companies listed on NASDAQ First North Denmark.

In our opinion, the financial statements give a true and fair view of the company's financial position on 30 June 2026 and of the results of the company's operations and cash flows for the financial period 1 January – 30 June 2026.

The management's review includes, in our opinion, a fair presentation of the matters dealt with in the report.

The interim report is unaudited.

Birkerød, 20 August 2026

Executive Management

Jakob Ole Knudsen
CEO

Board of Directors

Patrik Dahlen
(Chairman)

Valérie Soulier

Lars Kongsbak